Delegates at the recent 93rd Congress of the European Atherosclerosis Society (4-7 May 2025, Glasgow, UK) were left in no doubt of the importance of Lp(a) as a key risk factor for atherosclerotic cardiovascular disease (ASCVD), with new data from a major US study showing Lp(a) as a driver of recurrent ASCVD events. Further presentations […]
Elevated Lp(a) levels are associated with continuously increased risk of recurrent atherosclerotic cardiovascular disease (ASCVD) events, irrespective of sex and race/ethnicity, illustrating the unmet need for Lp(a) lowering therapy in diverse ASCVD populations.
Lp(a)-related relative risk of future coronary heart disease (CHD) events is similar for individuals at very low absolute risk (0/1 cardiovascular risk factors [CVRF]) and for those at elevated absolute risk with ≥2 CVRFs.
Reassuring data from 539,478 individuals in the Copenhagen General Population Study, the Copenhagen City Heart Study, and the UK Biobank show that low Lp(a) level does not increase the risk of Alzheimer’s disease or vascular-related dementia.
Some children with severely elevated Lp(a) can be identified during universal screening for familial hypercholesterolaemia (FH) but others will be missed if clinicians rely solely on Lp(a) testing in those with hypercholesterolaemia, reported Dr Matej Mlinarič, Ljubljana University Medical Centre, Slovenia.
Lp(a) ≥ 75 nmol/L has been associated with higher levels of non-culprit plaque rupture and non-culprit thin-cap fibroatheroma (TCFA) in patients with acute myocardial infarction (AMI).
